Plasmacure Showcases Cold Plasma Wound Therapy Outcomes in Resource-Limited Setting

According to a recent LinkedIn post from Plasmacure, the company’s cold plasma therapy device PLASOMA has been used in a low-income clinical setting on Sint Maarten. The post describes the island as a challenging wound-care environment, with more severe and complex diabetic foot ulcers than typically seen in the U.S. or Western Europe and limited access to advanced treatments.

The LinkedIn post highlights that PLASOMA was applied to long-standing diabetic foot ulcers, many of which had been open for more than a year, were moderately to severely infected, and had limited revascularization options. According to the content, the therapy nonetheless appears to have delivered “powerful” clinical results, with the company directing readers to case stories, numerical data, and outcome descriptions in an accompanying carousel.

For investors, the post suggests that Plasmacure is positioning PLASOMA as a viable option for complex wound care in resource-constrained markets, which could expand its addressable market beyond higher-income health systems. Demonstrated effectiveness in severe cases may strengthen the technology’s clinical value proposition and support future discussions with payers, clinicians, and potential commercial partners.

The focus on a low-income Caribbean setting may indicate a strategy to build evidence in diverse real-world environments, which can be important for regulatory dossiers, reimbursement negotiations, and international expansion. If further validated in formal studies, the type of outcomes hinted at in the post could underpin premium pricing, drive adoption in diabetic foot ulcer care, and enhance Plasmacure’s competitive position within the advanced wound care segment.